PHREESIA INC (PHR) Stock Fundamental Analysis
USA - NYSE:PHR - US71944F1066 - Common Stock
22.73 USD
+0.09 (+0.4%)
22.73 USD
0 (0%)
Taking everything into account, PHR scores 4 out of 10 in our fundamental rating. PHR was compared to 35 industry peers in the Health Care Technology industry. PHR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHR has reported negative net income.
PHR had a positive operating cash flow in the past year.
In the past 5 years PHR always reported negative net income.
In multiple years PHR reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a decent Return On Assets value of -5.89%, PHR is doing good in the industry, outperforming 68.57% of the companies in the same industry.
PHR has a better Return On Equity (-8.07%) than 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.89% | ||
| ROE | -8.07% | ||
| ROIC | N/A |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHR has a better Gross Margin (68.02%) than 65.71% of its industry peers.
PHR's Gross Margin has been stable in the last couple of years.
PHR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PHR has been increased compared to 1 year ago.
PHR has more shares outstanding than it did 5 years ago.
PHR has a worse debt/assets ratio than last year.
2.2 Solvency
PHR has an Altman-Z score of 5.83. This indicates that PHR is financially healthy and has little risk of bankruptcy at the moment.
PHR has a better Altman-Z score (5.83) than 82.86% of its industry peers.
PHR has a debt to FCF ratio of 0.42. This is a very positive value and a sign of high solvency as it would only need 0.42 years to pay back of all of its debts.
The Debt to FCF ratio of PHR (0.42) is better than 80.00% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that PHR is not too dependend on debt financing.
PHR has a Debt to Equity ratio of 0.02. This is in the better half of the industry: PHR outperforms 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.42 | ||
| Altman-Z | 5.83 |
ROIC/WACCN/A
WACC9.99%
2.3 Liquidity
A Current Ratio of 2.12 indicates that PHR has no problem at all paying its short term obligations.
The Current ratio of PHR (2.12) is comparable to the rest of the industry.
A Quick Ratio of 2.12 indicates that PHR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.12, PHR is in line with its industry, outperforming 45.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
PHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.50%, which is quite impressive.
PHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.31%.
The Revenue has been growing by 27.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.23%
Revenue 1Y (TTM)15.31%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.83%
3.2 Future
Based on estimates for the next years, PHR will show a very strong growth in Earnings Per Share. The EPS will grow by 40.97% on average per year.
Based on estimates for the next years, PHR will show a quite strong growth in Revenue. The Revenue will grow by 11.66% on average per year.
EPS Next Y96.48%
EPS Next 2Y52.47%
EPS Next 3Y40.97%
EPS Next 5YN/A
Revenue Next Year14.05%
Revenue Next 2Y13.08%
Revenue Next 3Y12.84%
Revenue Next 5Y11.66%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
PHR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 68.63, the valuation of PHR can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHR is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of PHR to the average of the S&P500 Index (22.53), we can say PHR is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 68.63 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHR is on the same level as its industry peers.
The rest of the industry has a similar Price/Free Cash Flow ratio as PHR.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48.82 | ||
| EV/EBITDA | 651.83 |
4.3 Compensation for Growth
PHR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHR's earnings are expected to grow with 40.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.47%
EPS Next 3Y40.97%
5. Dividend
5.1 Amount
PHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.73
+0.09 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners99.81%
Inst Owner Change1.07%
Ins Owners4.56%
Ins Owner Change-1.62%
Market Cap1.36B
Revenue(TTM)449.67M
Net Income(TTM)-24053000
Analysts85
Price Target34.61 (52.27%)
Short Float %6.56%
Short Ratio4.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)78.63%
Min EPS beat(2)41.66%
Max EPS beat(2)115.6%
EPS beat(4)4
Avg EPS beat(4)51.25%
Min EPS beat(4)8.94%
Max EPS beat(4)115.6%
EPS beat(8)8
Avg EPS beat(8)37.38%
EPS beat(12)12
Avg EPS beat(12)31.19%
EPS beat(16)15
Avg EPS beat(16)26.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.27%
Min Revenue beat(2)-0.37%
Max Revenue beat(2)-0.18%
Revenue beat(4)0
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-0.56%
Max Revenue beat(4)-0.18%
Revenue beat(8)2
Avg Revenue beat(8)-0.13%
Revenue beat(12)5
Avg Revenue beat(12)0.4%
Revenue beat(16)9
Avg Revenue beat(16)1.43%
PT rev (1m)-0.63%
PT rev (3m)5.52%
EPS NQ rev (1m)-60%
EPS NQ rev (3m)91.34%
EPS NY rev (1m)29.04%
EPS NY rev (3m)75.68%
Revenue NQ rev (1m)-1.02%
Revenue NQ rev (3m)-0.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 68.63 | ||
| P/S | 3.03 | ||
| P/FCF | 48.82 | ||
| P/OCF | 26.33 | ||
| P/B | 4.57 | ||
| P/tB | 9.6 | ||
| EV/EBITDA | 651.83 |
EPS(TTM)-0.42
EYN/A
EPS(NY)0.33
Fwd EY1.46%
FCF(TTM)0.47
FCFY2.05%
OCF(TTM)0.86
OCFY3.8%
SpS7.51
BVpS4.97
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.89% | ||
| ROE | -8.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% | ||
| FCFM | 6.2% |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
F-Score7
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.42 | ||
| Debt/EBITDA | 2.35 | ||
| Cap/Depr | 84.53% | ||
| Cap/Sales | 5.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 2655.34% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | 5.83 |
F-Score7
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)91.68%
Cap/Depr(5y)107.3%
Cap/Sales(3y)7.37%
Cap/Sales(5y)9.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.23%
EPS Next Y96.48%
EPS Next 2Y52.47%
EPS Next 3Y40.97%
EPS Next 5YN/A
Revenue 1Y (TTM)15.31%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.83%
Revenue Next Year14.05%
Revenue Next 2Y13.08%
Revenue Next 3Y12.84%
Revenue Next 5Y11.66%
EBIT growth 1Y73.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year249.5%
EBIT Next 3Y64.62%
EBIT Next 5Y37.25%
FCF growth 1Y132.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y186.75%
OCF growth 3YN/A
OCF growth 5Y108.09%
PHREESIA INC / PHR FAQ
Can you provide the ChartMill fundamental rating for PHREESIA INC?
ChartMill assigns a fundamental rating of 4 / 10 to PHR.
What is the valuation status for PHR stock?
ChartMill assigns a valuation rating of 3 / 10 to PHREESIA INC (PHR). This can be considered as Overvalued.
Can you provide the profitability details for PHREESIA INC?
PHREESIA INC (PHR) has a profitability rating of 2 / 10.
Is the dividend of PHREESIA INC sustainable?
The dividend rating of PHREESIA INC (PHR) is 0 / 10 and the dividend payout ratio is 0%.